{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-312571","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2026-07-22T21:19:38+00:00","discovered_at":"2026-07-22T21:22:00.290120+00:00","generated_at":"2026-07-22T21:22:09.700442+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Dyne Therapeutics prices upsized $375M public offering of 18.3M shares at $20.50/share","bullets":["Offering of 18,300,000 shares at $20.50/share; gross proceeds $375.15M.","Net proceeds estimated at $352.1M, or $405.0M if underwriters' option exercised.","Underwriters granted 30-day option to purchase up to 2,745,000 additional shares.","Closing expected July 23, 2026; proceeds extend cash runway into Q2 2028.","Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, Raymond James are joint book-runners."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-312571","json":"https://secwatch.observer/filing/0001193125-26-312571.json","markdown":"https://secwatch.observer/filing/0001193125-26-312571.md","text":"https://secwatch.observer/filing/0001193125-26-312571.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526312571/0001193125-26-312571-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526312571/d112911d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-22T21:22:09.700442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}